Information pack for specialist applicants Lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE The appointment of specialist members to NICE Diagnostics Advisory Committee Information pack for specialist applicants Lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation The closing date for receipt of specialist applications is 02 January 2018, 5:00pm National Institute for Health and Care Excellence (NICE) Centre for Health Technology Evaluation Level 1a, City Tower Piccadilly Plaza Manchester M1 4BD Direct Line: 0161 219 3838 Main Switchboard: +44 (0)300 323 0140 Email: diagnostics@nice.org.uk Website: www.nice.org.uk Page 1 of 19

ABOUT THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. NICE was originally set up in 1999 as the National Institute for Clinical Excellence, a special health authority, to reduce variation in the availability and quality of NHS treatments and care. In 2005, after merging with the Health Development Agency, we began developing public health guidance to help prevent ill health and promote healthier lifestyles. Our name changed to the National Institute for Health and Clinical Excellence. In April 2013 we were established in primary legislation, becoming a Non Departmental Public Body (NDPB) and placing us on a solid statutory footing as set out in the Health and Social Care Act 2012. At this time we took on responsibility for developing guidance and quality standards in social care, and our name changed once more to reflect these new responsibilities. As an NDPB, we are accountable to our sponsor department, the Department of Health, but operationally we are independent of government. Our guidance and other recommendations are made by independent committees. The NICE Board sets our strategic priorities and policies, but the day to day decision-making is the responsibility of our Senior Management Team (SMT). Our offices are in London and Manchester. Read more about who we are and what we do in our Charter. LOCATION OF COMMITTEE AND ASSESSMENT SUB-GROUP MEETINGS Committee and assessment sub-group meetings are held in Manchester and dates are agreed well in advance. NICE s Manchester office location details are attached at the end of this document. REMUNERATION AND ALLOWANCES The Institute pays reasonable out of pocket expenses, including 1st class rail fares (procured as economically as possible) and hotel costs where necessary, to enable attendance at Committee meetings. General practitioner members are eligible to apply for the cost of locum cover to enable them to attend committee meetings. Lay members receive a daily allowance. Please visit the Patients and the Public pages for more information about lay applications for membership of the Committee. The cost of child care is met in circumstances where it can be shown that no reasonable alternative arrangements can be made. Please click here for a copy of the Travel and subsistence policy - committee members. TERMS AND CONDITIONS OF OFFICE Page 2 of 19

Specialist members of the Diagnostics Advisory Committee are appointed for the period required to develop guidance on their specialist subject. This normally requires attendance at two day-long Committee meetings an assessment sub-group meeting, spread out over approximately 10 months to one year. Successful applicants are required to sign a confidentiality agreement and Declaration of Interest form prior to sitting on a Committee. Committee members are expected to abide by NICE s Social Value Judgement policy. Applicants should take special note of NICE s code of practice for declaring and dealing with conflicts of interest. Any applicant with an interest which would require them to declare it and withdraw from the meeting is unlikely to be selected as a specialist Committee member. APPOINTMENTS All appointments are made on merit in accordance with the NICE policy: Appointments to Guidance Producing Bodies Advisory to NICE. This observes the Code of Practice of the Office of the Commissioner for Public Appointments (OCPA), who monitors appointments to all public bodies and ensures that all appointments are made on merit after fair and open competition. EQUALITY AND DIVERSITY NICE aims to promote a culture of equality and diversity. It aim to ensure equality of opportunity in that no applicant for the Diagnostics Advisory Committee receives less favourable treatment on the grounds of, but not limited to, sex, race, colour, religion, marital status, sexuality, age, ethnic origin or disability, or is not placed at a disadvantage by conditions or requirements which cannot be shown to be justifiable. The Institute also aims to create a diverse membership and promote equality, including race equality, by eliminating discrimination, harassment and victimisation. COMMITTEE AND ASSESSMENT SUB-GROUP TERMS OF REFERENCE Terms of reference for the Committee and the assessment sub-group are in appendix B. COMMITTEE STANDING ORDERS The standing orders for NICE advisory bodies are in appendix C. CRITERIA FOR DISQUALIFICATION The following paragraphs identify the main circumstances where an individual would not be allowed to serve as Chair or as a Committee member of NICE. I. anyone who has, within the preceding five years, been convicted in the United Kingdom of any offence or convicted elsewhere of an offence which, if committed in any part of the United Kingdom would constitute a criminal offence in that part, and in either case has been sentenced to a period of imprisonment (whether suspended or not) for a period of not less Page 3 of 19

than three months without the option of a fine, and which has not been quashed on appeal; II. anyone who is the subject of a bankruptcy restrictions order or an interim bankruptcy restrictions order; III. anyone who has been dismissed within the previous five years, otherwise than by reason of redundancy, from any paid employment with a health service body; IV. anyone who has had an earlier term of appointment as the chair or member of a health service body terminated in certain circumstances; V. anyone who (a) is the subject of a national NHS disqualification, (b) was refused nomination or approval to fill a vacancy for a medical practitioner pursuant to regulations made under section 29B(2A) of the Act and was not subsequently nominated or approved or included in a primary care list, (c) has been refused admission to a primary care list on grounds corresponding to the conditions referred to in section 49F(2), (3) or (4) of the Act and has not subsequently been included in a primary care list, (d) is conditionally included in a primary care list, (e) has been removed from a primary care list on any of the grounds set out in section 49F(2), (3) or (4) of the Act or by a direction of the NHS Tribunal and has not subsequently been included in such a list, (f) is contingently removed from a primary care list, or (g) is suspended from a primary care list or treated as so suspended by virtue of regulation 6(2) of the Abolition of the National Health Service Tribunal (Consequential Provisions) Regulations 2001 or regulation 6(2) of the Abolition of the National Health Service Tribunal (Consequential Provisions) Regulations 2002, and in this sub-paragraph any reference to a provision in the Act includes a reference to the provision corresponding to that provision in legislation relating to Scotland and Northern Ireland; VI. anyone who is subject to a disqualification order under the Company Directors Disqualification Act 1986, the Companies (Northern Ireland) Order 1986 or to an order made under section 429(2)(b) of the Insolvency Act 1986 (disabilities on revocation of administration order against an individual); VII. anyone who has been removed from the office of charity trustee or trustee for a charity by an order made by the Charity Commissioners or the High Court on the grounds of any misconduct or mismanagement in the administration of the charity for which he was responsible or to which he was privy, or which he, by his conduct, contributed to or facilitated, or removed under section 7 of the Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (powers of Court of Session to deal with management Page 4 of 19

of charities) from being concerned in the management or control of any body. RECRUITMENT PROCESS The advertisement, role description and person specification give details of the specific vacancy for which you can apply. Specialist members of standing advisory committees are appointed following public advertisement, and submission of a CV with covering letter and a declaration of interest form. We will acknowledge receipt of your application. Please follow up your application if you do not received this. A panel will first assess your cover letter, curriculum vitae and any interests declared, to see whether you have the general personal qualities and skills specified for the post for which you have applied. From this the panel will decide appointments. Candidates may be contacted by a member of the appointment panel for a short telephone interview If you are successful, you will receive a letter from the Chair of the Committee appointing you as a specialist member of the Diagnostics Advisory Committee. All candidates will be required to submit a completed Declaration of Interests form and Confidentiality Agreement prior to any appointment. Unsuccessful candidates will be contacted. We will deal with your application as quickly as possible and will advise you of the likely timetable at each stage. The closing date for receipt of applications is 02 January 2018, 5:00pm Page 5 of 19

DEALING WITH YOUR CONCERNS In the first instance: For queries about your application, please call the Diagnostics Assessment Programme team on 0161 219 3839. If you are not completely satisfied: We aim to process all applications as quickly as possible and to treat all applicants with courtesy. If you feel that you have any complaints about the way your application has been handled, we would like to hear from you. Please write to: David Coombs Associate Director National Institute for Health and Care Excellence (NICE) Centre for Health Technology Evaluation Diagnostics Assessment Programme, Level 1a, City Tower, Piccadilly Plaza, Manchester M1 4BD Page 6 of 19

Appendix A NICE MANCHESTER OFFICE Address: National Institute for Health and Care Excellence Level 1A, City Tower Piccadilly Plaza Manchester M1 4BD Telephone: +44 (0)300 323 0140 Fax: +44 (0)300 323 0149 Email: Website: nice@nice.org.uk http://www.nice.org.uk/ Travel by train: Both Manchester Piccadilly and Oxford Road stations are a short walk from the office. Travel by aeroplane: Manchester International Airport is approximately 20-25 minutes drive. Travel by tram: Metrolink services run regularly from Victoria and Piccadilly stations to Piccadilly Gardens. Page 7 of 19

APPENDIX B: Terms of reference of Committee and assessment sub-group Diagnostics Advisory Committee Terms of Reference and Standing Orders Terms of reference General 1. The Diagnostics Advisory Committee will operate as a standing advisory committee of the Board of NICE. 2. The Diagnostics Advisory Committee will advise NICE on the formulation of NICE s Guidance on diagnostic technologies and any other matter related to the evaluation of diagnostic technologies, as requested. 3. The Diagnostics Advisory Committee will develop recommendations for the NHS in accordance with the Institute s published methods and processes for developing guidance on diagnostic technologies. 4. The Diagnostics Advisory Committee will submit its recommendations to the NICE Guidance Executive which will act under delegated powers of the Board in considering and approving the recommendations. Membership 5. The membership will be appointed by NICE and shall reflect both the spread of interests and expertise required for the business of the committee and the Institute s values of equality and diversity. 6. The committee will normally have 25-30 voting members including the chair (depending on the number of co-opted members for the topic under consideration).the total number of standing members will be 22. 7. The membership will be drawn from the diagnostics, clinical and associated communities. 8. The total membership of the Committee will include those with specific expertise in the technology or condition under consideration who will be coopted onto the Committee for the duration of its consideration of the topic. There will be no maximum number of co-opted members. They will engage with formulating recommendations and have voting rights, and their number will count towards the quorum of the meeting. Page 8 of 19

Diagnostics Advisory Committee (DAC) assessment sub-group Terms of reference Purpose of the assessment sub-group The purpose of the assessment sub-group is to ensure that the scope of the topic being assessed and the assessment protocol (the workplan of the external assessment group) and analyses are appropriately informed by the specialist knowledge and expertise of DAC members. NICE is responsible for ensuring that the evidence presented to DAC is of an appropriate standard and content for decision-making. The assessment sub-group does not replace NICE s responsibility. Constitution of the assessment sub-group An assessment sub-group is set up for each topic being assessed. It normally comprises: 1. Specialist Committee members for that topic 2. Chair of Diagnostics Advisory Committee (DAC) 3. Two standing members of DAC 4. NICE technical staff. The two standing members are chosen by the DAC chair. The assessment sub-group is normally chaired by the DAC chair or deputy chair. It may also be chaired by the associate director at the discretion of the chair. The external assessment group (EAG) is invited to the meeting(s) of the sub-group. Activities of the assessment sub-group The assessment sub-group meets once approximately one month after the scoping workshop to: Review the revised scope (produced after the scoping workshop), suggesting amendments if necessary Discuss and advise on the assessment protocol with the external assessment group. Membership of the assessment sub-group does not replace the overall responsibility of individual specialist or standing Committee members to contribute to the development of guidance. A lead team for each topic presents evidence assessment and analysis to the DAC. The lead team is selected by the DAC chair from the members of the assessment subgroup. The lead team consists of the DAC chair, 1 specialist Committee member and 1 standing Committee member. Relationship between the assessment sub-group and DAC Activities of the assessment sub-group are reported to DAC via meeting notes from sub-group meetings and verbal reports from the DAC chair. Notes from assessment sub-group meetings are published on the NICE website. 15 June 2010 Page 9 of 19

APPENDIX C Standing Orders for NICE Advisory Bodies General 9. These standing orders ( the SOs ) describe the procedural rules for managing the committee s work as agreed by NICE. The committee will operate as an advisory committee to NICE. Nothing of these standing orders shall limit compliance with NICE s Standing Orders so far as they are applicable to this committee. 10. The appointment of advisory committees is at the sole discretion of NICE s Board subject to any direction as may be given by the Secretary of State. 11. Members of the committee shall be bound by these standing orders and will be expected to abide by the seven principles for the conduct of public life as recommended by the Nolan Committee which are: selflessness integrity objectivity accountability openness honesty leadership 12. Other members who may be co-opted from time to time at the discretion of the committee shall be subject to the same principles. 13. The chair and members of the committee will be appointed in accordance with NICE s recruitment and selection to advisory bodies and topic expert groups policy and procedure. 15. The chair and members of the committee will be appointed for a period of 3 years in the first instance. This may be extended by mutual agreement for a further period of up to 3 years and up to a maximum of 10 years. 16. The removal or substitution of members and the general constitution of the advisory body shall be at the discretion of NICE in accordance with its published procedures. 17. All reasonable facilities shall be provided for members to ensure they have the opportunity to participate fully and equitably in the business of the committee. Interpretation 18. During the course of the meeting, the chair of the committee having taken advice from a senior member of the NICE committee project team shall be the final authority on the interpretation of standing orders. 19. Statements of committee members made at meetings shall be relevant to the matter under discussion at the time and the decision of the chair on questions of order, relevancy, and interpretation (including conflicts of interest) shall be final. Page 10 of 19

Committee chair and vice chair 20. Meetings will be conducted by the chair or in his/her absence the vice chair. 21. The vice chair will be appointed in accordance with NICE s recruitment and selection to advisory bodies and topic expert groups policy and procedure. 22. The vice chair s appointment will be for a period of 3 years in the first instance, renewable for a further period, of no more than 3 years, to a maximum of 10 years. 23. Where a committee member has been promoted from within the committee to vice chair, the new term will count against the 10 year total. For example, if a member serves one 3-year term and is then promoted to vice chair for another 3-year term, this will be regarded as having served 6 years as a member of the committee 24. The chair, or the vice chair in the chair s absence, may take action on behalf of the committee outside of the scheduled committee cycle when urgent decisions are required and it is impracticable to convene a special meeting of the committee. 25. On the occasion(s) where the chair or the vice chair is absent, another member of the committee can be used as proxy to fulfil the role. The proxy vice chair of the meeting will be appointed by the centre director (or an appointed deputy) and the chair of the meeting. Quorum 26. The quorum is set at 50% of committee membership in accordance with ToR. The quorum should be rounded up to the next whole number in the event of there being an odd number of members. 27. No business should be transacted unless the meeting is quorate. If a member is excluded due to a conflict of interest and membership falls below the quorum, no business may be transacted. There is no time limit for a quorum to be achieved but the start of the meeting or business transaction should be delayed where the meeting is not quorate. 28. The quorum must be achieved for the meeting to proceed. However, the needs of the committee are such that even if the meeting is quorate, an appropriate spread of members interests should be represented at each meeting. If, in the view of the chair, the spread of interests is insufficient for the business under consideration, the meeting may be suspended or adjourned until a later date. 29. Invited experts and observers in attendance at committee meetings will not count towards the quorum. Voting 30. The decisions of the committee will normally be arrived at by a consensus of committee members present. Voting will only be used for decision-making in exceptional circumstances. Before a decision to move to a vote is made, the chair will, in all cases, consider whether continuing the discussion at a subsequent meeting is likely to lead to consensus. 31. Voting will be anonymous and decisions determined by a simple majority of committee members present at a quorate meeting. Page 11 of 19

32. The chair of the meeting will be included in the vote and in the event of there being an equality of votes the chair will have a second, casting vote. 33. Only committee members present at the meeting will be eligible to vote. There will be no proxy voting. 34. Invited experts and observers in attendance at committee meetings will not be eligible to vote. Collective responsibility 35. All members of the committee shall abide by the principle of collective responsibility, stand by the recommendations of the committee and not speak against them in public. Confidentiality 36. On appointment, committee members will be required to sign a confidentiality agreement with NICE relating to any information designated confidential by NICE such as academic or commercial-in-confidence material or sensitive personal data. 37. Confidential papers and confidential information disclosed in committee deliberations should not be discussed with colleagues who are not members of the committee, other organisations, the media, or members of the committee who are conflicted for the topic. 38. Experts, co-opted members and observers invited by the committee will sign a confidentiality agreement in advance and be subject to the same confidentiality regulations as committee members. Arrangements for meetings 39. NICE will ensure that committee meetings will take place in venues that are accessible to, and have facilities for, persons with disabilities. 40. Meetings of the committee shall be held at such times and places as NICE may determine to facilitate the conduct of its business. The frequency of the meetings is detailed in the Diagnostics Assessment Programme Manual. 41. NICE shall determine what matters shall appear on every agenda in advance of each meeting. 42. No other business shall be discussed at the meeting save at the discretion of the chair. 43. Where considered necessary because of the confidential nature of the business to be transacted, the agenda will be divided into two parts. Part 1 will be open to the public and part 2 will be closed to the public to enable the committee to discuss confidential information whereupon SO paragraph 52 will apply. 44. Only members of the committee and NICE staff, co-opted members, observers invited by NICE, and assessment groups will be present for part 2 of the meeting. However, at the discretion of the chair, experts such as a manufacturer representative may be invited to remain in order to discuss confidential information that was not discussed in part 1. Once the information concerned has been discussed, the representatives will leave the meeting and will take no further part Page 12 of 19

in its deliberations. 45. At least 20 working days before each meeting of the committee, a public notice of the time and place of the meeting, along with the public part of the agenda, shall be displayed on NICE s website. The final agenda will be displayed on the NICE website at least 5 working days before the meeting. 46. Meetings will normally commence at 10am and finish at approx. 4.30pm unless otherwise advised. 47. Committee members will be expected to attend for the full day unless agreed in advance with the chair or where they have declared a conflict of interest to one or more relevant discussions. 48. The NICE committee project team will make all reasonable attempts to agree each meeting date in advance and committee members are expected to keep these dates free until they are released. Admission of members of the public 49. Where advisory committee meetings are open to the public, the following provisions will apply. 50. The public and representatives of the press shall be afforded facilities to observe all formal meetings of the committee for part 1 of the agenda but shall not be entitled to ask questions or otherwise engage in the business of the committee. 51. The public and representatives of the press shall be excluded from part 2 of the committee meeting upon the chair moving the following motion: That representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity in which would be prejudicial to the public interest [section 1(2) Public Bodies (Admissions to Meetings) Act 1960]. 52. Notwithstanding the above, the chair will have the discretion to adjourn the meeting at any time if the presence of the public or representatives of the press are considered prejudicial to the effective conduct of the business of the meeting upon moving the following motion: That in the interests of public order the meeting adjourn for (the period to be specified by the chair) to enable the Committee to complete business without the presence of the public [section 1(8) Public Bodies (Admission to Meetings) Act 1960]. Other observers 53. NICE staff and invited guests (for example, NICE appeal panel members or visiting academics) may attend committee meetings as observers, with the permission of the centre director. 54. Observers do not need to register via the website. Observers should not sit with members of the public and should not enter into committee discussions unless invited to do so by the chair. Page 13 of 19

55. Observers can attend part 2 of the meeting if the chair and centre director agree. Observers who are not NICE staff or are not commissioned to provide a service to NICE should sign a confidentiality agreement if they wish to attend part 2 of the meeting. Minutes 56. The draft minutes of the committee proceedings shall be drawn up and submitted to the next meeting for approval. 57. The approved minutes will be published on NICE s website subject to the redaction of any confidential or otherwise exempt material within 20 working days of the meeting. Declarations of Interest 58. All committee members must make an annual declaration of interests in accordance with NICE s Code of Practice on the Declaration of Interests. 59. All members must make a declaration of any potential conflicts of interest that may require their withdrawal in advance of each meeting. This declaration will be reaffirmed again at the start of each meeting. Declarations of interest will be recorded in the minutes and published on the NICE website. 60. During the course of the meeting, if a conflict of interest arises with matters under consideration, the member concerned must withdraw from the meeting, or part thereof, as appropriate. 61. Experts invited to provide expert testimony, and co-opted members will make a declaration of interest in advance of committee meetings and in accordance with NICE s Code of Practice on the Declaration of Interests. This declaration will be reaffirmed again at the start of each meeting. These will be recorded in the minutes and published on the NICE website. Suspension of standing orders 62. Except where this would contravene any statutory provision, any one or more of the standing orders may be suspended at any meeting providing a simple majority of those present and eligible to participate, vote in favour of the suspension. 63. Any decision to suspend standing orders shall be recorded in the minutes of the meeting. 64. No formal business may be transacted while standing orders are suspended. 65. NICE s Audit Committee shall review all decisions to suspend standing orders. Petitions 66. Petitions from the public will not be received directly by the committee. Anyone wishing to present a petition will be directed to the NICE committee project team. Recording of meetings 67. The recording of proceedings or the taking of pictures at committee meetings is not allowed. Page 14 of 19

Terms of reference 68. Committee members must comply with the terms of reference which set out the scope of the committee s work and its authority. Record of attendance 69. A record will be kept of committee members attendance at committee meetings via the minutes. 70. Members are expected: to attend at least 75% of their committee s meetings during a 12-month period. not to miss more than 2 consecutive committee meetings. 71. Members who are unable to meet either of these expectations may be asked to stand down from the committee in accordance with SO paragraph 16. Review of terms of reference and standing orders 72. These terms of reference and standing orders will be reviewed every 3 years. Date: August 2013 Review date: August 2016 Page 15 of 19

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Role Lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation Lead-I electrocardiogram (ECG) devices are hand held devices which can be used in primary care to aid the detection of atrial fibrillation. The devices include touch electrodes, internal storage for ECG recordings and automated software which can interpret the ECG trace and allow data to be transferred to a computer for further analysis by a healthcare professional. Where atrial fibrillation is detected by a lead-i ECG device, a 12 lead ECG is required to confirm the diagnosis. It is claimed that using lead-i ECG devices can result in more accurate detection of atrial fibrillation than manual pulse palpation alone. More accurate detection of atrial fibrillation may lead to earlier identification of people who are at risk of having a stroke and who will benefit from treatment with anticoagulants or anti-arrhythmic medications. The NICE Diagnostics Assessment Programme will assess the clinical and cost-effectiveness of lead-i ECG devices in order to make recommendations on their use in the NHS. The National Institute for Health and Care Excellence (NICE) is looking to recruit to the Diagnostics Advisory Committee (DAC) healthcare professionals with specialist knowledge of the above topic. Centre Centre for Health Technology Evaluation Page 16 of 19

ROLE DESCRIPTION Summary The Diagnostics Advisory Committee considers and interprets evidence on the clinical and cost effectiveness of diagnostic technologies as defined in the relevant EU directives, and formulates recommendations to the Institute on their use in the National Health Service. Temporary specialist members join the Committee for the discussion and decision-making meetings on the given topic. We are seeking specialists in the following areas: Consultant cardiologist General Practitioner Nurse practitioner with an interest in atrial fibrillation Cardiographer/cardiac physiologist Applicants must be based in the UK. Responsibilities The position is for approximately 10 months. Attend the following meetings in central Manchester: o Assessment sub-group meeting: 06 February 2018 o 1 st Diagnostics Advisory Committee meeting: 18 September 2018 o 2 nd Diagnostics Advisory Committee meeting: 20 November 2018 Attendance is desirable at the scoping workshop: 22 January 2018, from 10:30am On behalf of the Committee, advise the external assessment group on request during the assessment phase. This may include advice on the care pathway, the selection and analysis of the evidence, and other issues relevant to the assessment of the topic that require specialist clinical or methodological expertise Contribute to the Committee s deliberations from their own specialist knowledge whilst respecting input from non-specialists and lay persons. Apply their own experience and judgement to the topics Page 17 of 19

Conditions under discussion, rather than act as a representative of their organisation Work with the other members of the Committee and NICE staff to identify key issues and review evidence Work with other members of the Committee and NICE staff to formulate recommendations and comment on the evidence and on drafts of the guidance Agree the draft and final recommendations Advise on implementation issues as required Ensure appropriate consideration of the implications of guidance for equalities Follow agreed decision-making procedures and accept the collective decisions of the Committee. Abide by NICE s code of conduct for Committee members including NICE s code of practice for declaring and dealing with conflicts of interest, and follow the Committee s operational procedures Prepare for the Committee meetings by reading the papers and by gathering any additional information on the proposed topics which may be helpful to the discussions Participate in induction training. Must be available for both Committee meetings and the assessment sub-group meeting(s) (dates outlined above) With the exception of lay members, Committee membership is unpaid although expenses, including overnight accommodation, are reimbursed. General practitioner members are eligible to apply for the cost of locum cover to enable them to attend Committee meetings. Accommodation, travel and subsistence expenses are paid in accordance with NICE s non-staff travel and subsistence policy. Page 18 of 19

PERSON SPECIFICATION Extent and nature of committee experience Essential An understanding of the social, political, economic and professional influences on NICE. Desirable Experience of expert committee work in a relevant setting. Ability to contribute to the work of the advisory body Experience in health or social care (as appropriate), either as: a practicing health or social care professional, or working in or in association with the wider aspects of health or social care or the healthcare industries. Active registration with the appropriate professional body Ability to understand and interpret multiple complex data sets Nature of the motivation underpinning the application Equality and diversity A licence to practise(for medical roles only) Ability to gather data, analyse, critique and synthesise complex information, as evidenced by relevant experience and/or academic qualifications. Clearly and persuasively stated reasoning for making an application. Commitment to eliminating unlawful discrimination, advancing equality and an understanding or awareness of the issues of inequality in health, public health and social care settings. Page 19 of 19